Gilead Sciences Inc Cash Flow Conversion Efficiency
Gilead Sciences Inc cash flow conversion efficiency. Based on the latest financial reports, Gilead Sciences Inc (GILD) has a cash flow conversion efficiency ratio of 0.304x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.57 Billion) by net assets ($11.74 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Gilead Sciences Inc (1990–2025)
Cash flow conversion efficiency of Gilead Sciences Inc from 1990 to 2025. This chart illustrates how Gilead Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Gilead Sciences Inc for real-time trading data and today's change.
Gilead Sciences Inc Cash Flow Conversion Ratio Explained
Gilead Sciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Gilead Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gilead Sciences Inc ranked by their cash flow conversion efficiency. Also see GILD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IND.D.D.TEXT.UNSP.ADR 1/2
F:IXD2
|
N/A |
|
Toyota Motor Corporation
F:TOM
|
0.021x |
|
Walt Disney Company
NYSE:DIS
|
0.042x |
|
MediaTek Inc
TW:2454
|
-0.044x |
|
Toyota Motor Corporation
F:TOMA
|
0.021x |
|
Reliance Industries Limited
LSE:RIGD
|
0.080x |
|
SIEMENS AG SP. ADR 1/ 1/2
F:SIEB
|
0.016x |
|
COMMONW.BK AUSTR.SP.ADRS
F:CWW0
|
N/A |
Annual Cash Flow Conversion Efficiency for Gilead Sciences Inc (1990–2025)
The table below shows the annual cash flow conversion efficiency of Gilead Sciences Inc from 1990 to 2025. Review GILD free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $22.62 Billion | $10.02 Billion | 0.443x | -21.27% |
| 2024-12-31 | $19.25 Billion | $10.83 Billion | 0.563x | +59.87% |
| 2023-12-31 | $22.75 Billion | $8.01 Billion | 0.352x | -17.72% |
| 2022-12-31 | $21.21 Billion | $9.07 Billion | 0.428x | -20.85% |
| 2021-12-31 | $21.06 Billion | $11.38 Billion | 0.540x | +20.56% |
| 2020-12-31 | $18.22 Billion | $8.17 Billion | 0.448x | +11.04% |
| 2019-12-31 | $22.65 Billion | $9.14 Billion | 0.404x | +3.49% |
| 2018-12-31 | $21.53 Billion | $8.40 Billion | 0.390x | -32.79% |
| 2017-12-31 | $20.50 Billion | $11.90 Billion | 0.580x | -34.08% |
| 2016-12-31 | $19.36 Billion | $17.05 Billion | 0.880x | -20.81% |
| 2015-12-31 | $19.11 Billion | $21.25 Billion | 1.112x | +37.21% |
| 2014-12-31 | $15.82 Billion | $12.82 Billion | 0.810x | +206.50% |
| 2013-12-31 | $11.74 Billion | $3.10 Billion | 0.264x | -21.03% |
| 2012-12-31 | $9.54 Billion | $3.19 Billion | 0.335x | -36.82% |
| 2011-12-31 | $6.87 Billion | $3.64 Billion | 0.530x | +14.47% |
| 2010-12-31 | $6.12 Billion | $2.83 Billion | 0.463x | -2.23% |
| 2009-12-31 | $6.51 Billion | $3.08 Billion | 0.473x | -1.35% |
| 2008-12-31 | $4.47 Billion | $2.14 Billion | 0.480x | -2.11% |
| 2007-12-31 | $3.60 Billion | $1.77 Billion | 0.490x | -24.77% |
| 2006-12-31 | $1.87 Billion | $1.22 Billion | 0.652x | +179.67% |
| 2005-12-31 | $3.03 Billion | $705.64 Million | 0.233x | -14.16% |
| 2004-12-31 | $1.87 Billion | $507.96 Million | 0.272x | +16.07% |
| 2003-12-31 | $1.00 Billion | $234.61 Million | 0.234x | +79.61% |
| 2002-12-31 | $571.34 Million | $74.41 Million | 0.130x | +146.40% |
| 2001-12-31 | $452.44 Million | $-126.98 Million | -0.281x | -157.96% |
| 2000-12-31 | $351.12 Million | $-38.20 Million | -0.109x | +48.33% |
| 1999-12-31 | $297.29 Million | $-62.60 Million | -0.211x | -36.97% |
| 1998-12-31 | $333.70 Million | $-51.30 Million | -0.154x | +10.50% |
| 1997-12-31 | $317.30 Million | $-54.50 Million | -0.172x | -203.65% |
| 1996-12-31 | $291.70 Million | $-16.50 Million | -0.057x | +62.74% |
| 1995-12-31 | $151.50 Million | $-23.00 Million | -0.152x | +52.29% |
| 1994-12-31 | $86.10 Million | $-27.40 Million | -0.318x | -63.81% |
| 1993-12-31 | $115.30 Million | $-22.40 Million | -0.194x | -204.29% |
| 1992-12-31 | $139.40 Million | $-8.90 Million | -0.064x | -82.22% |
| 1991-12-31 | $105.60 Million | $-3.70 Million | -0.035x | +85.11% |
| 1990-12-31 | $10.20 Million | $-2.40 Million | -0.235x | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatiti… Read more